|
Professor of Biological Sciences; Robert and Jane Meyerhoff Chair of Biochemistry
Postdoctoral, Johns Hopkins University, 1977; Ph.D., California Institute of Technology, 1975
Selected publications
Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. 2008. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes. Cancer Immunol. Immunother. 57:389-398. E-pub ahead of print.[Abstract] Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67:10019-10026.[Abstract] Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67:4507-4513. Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, and Ostrand-Rosenberg S. Tumor associated myeloid-derived suppressor cells. In: Cancer Immunotherapy: Immune Suppression and Tumor Growth. (Eds: George Prendergast and Elizabeth Jaffee. Chapter 17, p. 309. Elsevier Inc. June 2007. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983.[Abstract] Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. 2007. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67:4499-4506.[Abstract] Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne. 2006. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J. Immunol. 177:6018-6024[Abstract] Bunt SK, Sinha P Clements VK, Leips J and Ostrand-Rosenberg S. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176:284-290.[Abstract] Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S. 2006. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66:1147-1154.[Abstract] Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne. 2006. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 176:1447-1455.[Abstract]
|
